BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. OIG
5. NRIX
6. SUNS
7. ACI
8. SPY
9. SNDX
10. HUM

Go back to BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

BioMarin Reports First Quarter 2026 Financial and Operating Results

May 4, 2026 4:05 PM EDT

First Quarter 2026 Total Revenues Increased Year-over-year to $766 million

Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y/Y at the Midpoint, and Reflecting the Addition of GALAFOLD® and POMBILITI® + OPFOLDA® to BioMarin's Portfolio

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., May 4, 2026 /PRNewswire/ -- BioMarin... More